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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.11.001We describe an unusual case of severe combined immunodeficiency (SCID) with neutropenia and central
nervous system (CNS) manifestations in which a novel RAG1 mutation was identified. A 15-month-old
boy presented with failure to thrive, neutropenia and recurrent infections. He was diagnosed with T-B-
NK+ SCID. He subsequently developed right partial seizures with ipsilateral hemiparesis and became
comatose. Magnetic resonance imaging (MRI) of the brain revealed an inflammatory lesion in the left thal-
amus which later progressed to diffuse meningo-encephalitis on serial imaging. No CNS infection was
documented. Genetic work-up in the child revealed a novel homozygous deleterious mutation in the
RAG1 gene (c:2881T>C; p:I794T), for which both parents were heterozygous. He underwent a haplo-
identical bone marrow transplant without conditioning and died on day +35 with no improvement in
his neurological status. The features of neutropenia and progressive encephalopathy could be linked to
the novel genetic defect but more data is required to establish this conclusively.Severe combined immunodeﬁciency (SCID)represents a heterogeneous group of disorderscharacterised by impairment in both cellular
and humoral immunity. SCID arises from mutations
of genes critical to the development of the adaptive
immune system. The deﬁning characteristic is a pro-
found depletion of circulating lymphocytes resulting
in markedly increased susceptibility to severe infec-
tions from early infancy. The only form of curative
therapy for this potentially fatal disorder is hemato-
poietic stem cell transplantation. Recombinase activat-
ing genes 1 and 2 (RAG1 and RAG2) play a vital role
in the process of re-arrangement of the variable (V),
diversity (D) and joining (J) segments during the
development of the T cell and immunoglobulin recep-
tors, a process crucial for antigenic diversity.1 The
association between B cell negative SCID and
RAG1 and RAG2 genes was ﬁrst described by Klaus
et al. in 1996.2 Since then numerous mutations atHeRAG1 or RAG2 locus on chromosome 11p23 have
been described, resulting in a diverse clinical spec-
trum.3 These mutations are broadly classiﬁed into
RAG deﬁcient SCID (RAGD) with no V (D) J
recombination (<1% recombination activity of wild
type), and RAGD with residual V (D) J recombina-
tion (>1% recombination activity of wild type).4
We report an unusual case of T-B-NK+ SCID with
neutropenia and progressive encephalopathy in which
a novel homozygous missense RAG1 mutation was
identiﬁed.CASE REPORT
We report the case of an 11-month-old boy of Indian
descent, second born of a consanguineous marriage
who was delivered at term after an uneventful preg-
nancy. He presented with complaints of failure to gain
weight, recurrent respiratory tract infections and loosematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
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stools since the age of 5 months. Developmentally, the
child exhibited features of mild motor and mental
impairment. He had no vision, hearing or motor deﬁ-
cits. He had received multiple courses of oral (amoxi-
cillin–clavulonate and oﬂoxacin) and intravenous
antibiotics (ceftriaxone) in the past but his symptoms
persisted and he was referred to our centre for further
evaluation. At presentation the child was febrile and
tachypneic with mild chest retractions. Respiratory
system examination revealed coarse bilateral crepita-
tions. There was no organomegaly, lymphadenopathy,
oral thrush, ear discharge or skin rash. The rest of the
systemic examination was unremarkable. Complete
blood count done on admission showed a haemoglobin
of 9.9 g/dl, total leukocyte count (TLC) of 5300/ll
with an absolute neutrophil count (ANC) of 159/ll,
an absolute lymphocyte count of 2800/ll and platelet
count of 265000/ll. Peripheral smear showed micro-
cytic hypochromic anemia with no evidence of hemoly-
sis. To reduce cost of investigation in this admission, a
bone marrow was not performed. Tests for hepatic and
renal function were normal. Chest X-ray showed evi-
dence of bilateral diffuse pneumonitis with a normal/
small thymic shadow. Anti-mycobacterial therapy
(AMT) comprising isoniazid, rifampicin, ethambutol
and pyrizinamide was started presumptively in view
of maternal history of tuberculosis which was ade-
quately treated 9 months back. His blood culture
and bronchio-alveolar lavage were negative for any bac-
terial or fungal pathogen. On immunological evalua-
tion he was found to have hypogammaglobulinemia,
T and B cell lymphopenia (CD4+, CD8+ and
CD19+) and normal CD56+ cells. Detailed investiga-Table I. Summary of immunological evaluation.
Patient Normal range
Immunoglobulins (mg/dl)
Ig A 1 4–90
Ig M 17 25–150
Ig G 89 200–1000
Ig E 3.6 <35
Peripheral blood lymphocyte subset
CD 3 576/ll 1460–5440/ll
CD 4 320/ll 1020–3600/ll
CD 8 134/ll 570–2230/ll
CD 19 6/ll 430–3300/ll
CD 56 369/ll 80–340/ll
Hematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comtions are summarised in Table I. He was diagnosed as a
case of T-B-NK+ severe combined immunodeﬁciency
(SCID) with neutropenia, and advised regarding a
hematopoetic stem cell transplant. His elder sibling,
a six-year-old female was only a 3/6 match at HLA
loci, and a search for an unrelated donor unit was ini-
tiated but his parents were unwilling to have an unre-
lated donor transplant. He was discharged on request
on AMT, antifungal (ﬂuconazole), co-trimoxazole for
Pneumocystis jirovici prophylaxis and intravenous
immunoglobulin at three-week intervals.
The child was readmitted to the hospital 4 months
later on account of fever, diarrhoea and right henicon-
vulsions. He was in a state of shock and the sensorium
was obtunded. Emergency measures were instituted
with parenteral ﬂuids, antibiotics and anticonvulsants.
His condition stabilised, the sensorium remained obt-
unded and a right hemiplegia was detected. Investiga-
tions revealed a haemoglobin of 9.2 g/dl, TLC of
1400/ll and platelet count of 14,000/ll and an abso-
lute neutrophil count (ANC) of 336/ll. Serum elec-
trolytes, hepatic and renal functions were in the
normal. MRI of the brain revealed a 2 · 1.2 · 2 cm
area in the left thalamus, showing bright signal inten-
sity on T-2 weighted images and low signal intensity
on T-1 weighted images (Figure 1A). The possibility
of an infarction or infective pathology was considered.
A lumbar tap yielded cerebrospinal ﬂuid (CSF) under
normal pressure. Biochemistry, cytology and staining
for bacteria and fungi were negative. A detailed
work-up for an infective etiology was conducted. Cul-
tures and PCR studies were done in blood and found
to be negative for all common bacterial, fungal and
viral pathogens which included toxoplasma, mycobac-
terium tuberculosis, mycoplasma pneumonia, cyto-
megalovirus, Ebstein–Barr virus, parvovirus, rubella,
herpes-simplex virus, JC virus, human immunodeﬁ-
ciency virus, herpes-simplex virus, Japanese encephali-
tis and adenovirus. We could not test for poliovirus,
enterovirus and measles. Testing for antibodies
against NMDA (N-methyl D-aspartate) receptor was
also negative in blood and CSF. The details of inves-
tigations conducted are summarised in Table II. His
chest X-ray showed persistent bilateral nodular inﬁl-
trates and AMT was continued. He was empirically
started on treatment with broad spectrum antibiotics
(Meropenem/Amikacin/Teicoplanin), antifungal (IV
caspofungin), antiviral (IV acyclovir), antiprotozoal
(sulfadoxine–pyrimethamine) drugs, and anti-convul-
sants (sodium valproate, phenobarbitone and leveti-
racetam). IVIG infusions were given to boost
immunity. The condition of the child remained criti-
cal. Follow-up MRI brain scans showed extensive dis-45
Figure 1. The MRI done at admission (A) reveals hyper-intensities predominantly in the left temporal and frontal lobes with hyper-intense foci seen in the left thalamus and
subtle hyper-intensities in the brainstem. The scan obtained 3 weeks later (B) shows rapid progression of the disease with increased areas of signal abnormality in both
cerebral hemispheres as well as the brainstem. The brain shows early atrophic changes. On the last scan (C) the atrophic/gliotic changes have progressed further with areas
of T1 hyper-intensity. No diffusion restriction or enhancement were noted at any time.
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gion, left insular cortex and cingulate gyrus. Increased
signal intensities were noted in the right cingulate
gyrus and temporo-parietal areas, affecting the cortex
and white matter (Figure 1B). MR arteriography and
venography excluded an arteritis or occlusive cerebro-
vascular disease. Electro-encephalography (EEG) re-
vealed bilateral periodic lateralised epileptiform
discharges (bi-PLEDs) and later EEGs showed a
burst suppression pattern. In view of his altered sen-
sorium and uncontrolled seizures, emergency manage-
ment of refractory/super-refractory status epilepticus
with midazolam continuous infusion, increased dos-
ing of ongoing anti-convulsants was carried out. The
child was intubated and mechanical ventilation insti-
tuted. At this juncture, the parents insisted on deﬁn-
itive therapy in the form of stem cell transplant, and
they were counselled appropriately regarding the risks
and prognosis. However, after detailed discussion
with the family, a decision was taken to proceed with
a haploidentical stem cell transplant with the mother
as donor. Pre-transplant chimerism analysis of the pa-
tient did not show any evidence of maternal micro-
engraftment. Unmanipulated bone marrow graft was
infused with a CD34 cell dose of 5.5 million/kg of re-Hecipient weight. No conditioning was given, and post-
transplant immune-suppression comprising cyclo-
phosphamide (50 mg/kg) on day +3 and day +4,
tacrolimus (1 mg/kg once daily) and mycophenolate
mofetil (15 mg/kg thrice daily) from day +5, was gi-
ven. Tacrolimus levels were monitored and doses
modiﬁed to maintain trough levels between 5 and
10 ng/ml. The patient continued to receive prophy-
lactic antibiotics, anti-fungal, antiviral and anti-tuber-
cular drugs as described before. FISH for XX and
XY chromosomes to look for engraftment on day
+19 showed 2% maternal cells, but was subsequently
negative for donor cells on day +29, and day +35.
Post-transplant, he remained on mechanical ventila-
tion and seizures persisted. The patient also had per-
sistent dyselectrolytemia (hypernatremia and
hypokalemia), hypoalbuminemia, and hypertension
which were medically managed. Irradiated blood
products were given as required. Neuro-imaging was
repeated in view of seizures which showed extensive
encephalomalcia in both cerebral hemispheres (Figure
1C). He remained obtunded with GCS of 3/15.
The patient developed multi drug resistant Chry-
seobacterium indologenes sepsis with multi-organ fail-
ure. Antibiotics were changed as per blood culturematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
Table II. Details of investigations at the onset of neurological
symptoms.
Blood
Complete blood
count
Hb-9.2 g/dl, TLC-1400/ll, platelet count –
14,000/ll, ANC-336/ll
Culture Negative
CMV PCR
(quantitative)
Negative
EBV PCR Negative
Toxoplasma PCR Negative
CSF
Cell count and
differential
2 lymphocytes
Protein/sugar(mg/
dl)
16/84
Culture Negative
EBV PCR Negative
CMV PCR Negative
HSV PCR Negative
Toxoplasma PCR Negative
JC virus PCR Negative
Adenovirus PCR Negative
RAGI MUTATION IN SCID case reportsensitivity reports. He died on day +35 post-trans-
plant with rejection of donor cells and no improve-
ment in the neurological status. A brain biopsy was
planned, but was refused by the family.Figure 2. Pedigree chart showing a novel homozyg
Hematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comBlood samples of the patient and both parents
were sent to France for precise identiﬁcation of the ge-
netic defect. Molecular sequencing revealed a novel
homozygous mutation in the RAG1 gene (c:2381
T>C; p:I794T) in the child (Figure 2) for which both
parents were heterozygous. Sequencing of RAG2 lo-
cus and Artemis genes did not reveal any abnormality.DISCUSSION
Mutations in RAG1 and RAG2 genes account for
50% of cases of T-B-NK+ SCID.5 The spectrum of
disorders resulting from RAG1 and RAG2 mutations
varies from classical SCID and classical SCID with
materno-fetal transfusion (with no V (D) J activity)
to partial deﬁciency resulting in Omenn’s syndrome
and granulomatous inﬂammation.4 In our case, we
could not test for RAG protein expression and func-
tional assay for lymphocyte proliferation as these tests
are not available in India. This disorder is mostly
associated with a T-B-NK+ phenotype but other
variants are also described.6 We identiﬁed a novel
mutation in the RAG1 gene for which the child was
homozygous and both parents were found to be het-
erozygous. He had an unusual clinical phenotype
which we hypothesised to be related to the unique ge-
netic defect.
This patient had initially presented with isolated
neutropenia but later on he developed depression of
all cell lines. Classically severe neutropenia has been
described in conjunction with reticular dysgenesis.7
Niehues et al. described neutropenia in a case of
SCID with materno-fetal transfusion which was
responsive to G-CSF therapy.8 Radiosensitive SCID
variants with defects in non-homologous end joiningous mutation identified as RAG1: c.2381 T>C; p. Ile794Thr in the child.
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have features akin to Nijmegen breakage syndrome9
and typically present with pancytopenia. These in-
clude ligase-IV syndrome,10 and hypomorphic muta-
tions in Artemis.11 In our patient, the neutropenia
at presentation could be ascribed to the multiple anti-
biotics he had received previously – all of which are
known to cause agranulocytosis. However, we specu-
late that it could be linked to his genetic defect. In
RAGD, neutropenia has not been described so far
and we believe that this is peculiar to the new muta-
tion identiﬁed in our patient.
Central nervous system (CNS) involvement in
SCID is a rare occurrence and difﬁcult to diagnose
as signs and symptoms may be subtle and a high index
of suspicion is necessary. It is usually secondary to
infections or neurotoxic medications but in certain
variants of SCID, primary CNS pathology has also
been described. Neurological manifestations are most
commonly seen in patients with adenosine deaminase
(ADA) deﬁciency and include motor dysfunction,
developmental delay, cortical blindness, sensorineural
deafness and behavioural abnormalities.12,13 In
ADA-deﬁcient SCID, the CNS insult is thought to
result from toxic accumulation of adenosine in the
brain especially in areas rich in adenosine receptors
such as the basal ganglia and thalamus. These abnor-
malities may persist or can occur post-transplant as
well.14 Recent data has thrown light on association
of FOXN1 mutations in NUDE/fetal SCID with
multiple site neural tube defects, thymic aplasia as
well as alterations of corpus callosum and reduction
in cerebellar Purkinje cells.15–17 Interestingly in our
patient too, the lesion was ﬁrst noted in the thalamus.
Other forms of SCID with CNS damage are DNA
ligase IV deﬁciency,10 and spastic diplegia, character-
istically seen in purine nucleoside phosphorylase deﬁ-
ciency.18 CNS infections in SCID are infrequently
described in literature. Waruiru et al. found an inci-
dence of 10% in their cohort of 79 patients of
SCID.19 They described eight patients of SCID
(including three with RAGD and two with T-B-
NK+ SCID of undetermined origin) with viral infec-
tions in CNS conﬁrmed by PCR-based techniques.
CSF cell count and biochemistry was abnormal in
four cases. The CSF analysis in our case was abso-
lutely normal. The aetiopathogenesis of the acute
and progressive CNS deterioration in our patient re-
mains undecided. The primary manifestation of
immunodeﬁciencies is undue susceptibility to infec-
tion. Progressive neuro-degeneration in primary
immunodeﬁciency has been demonstrated in experi-
mental animals and humans. Ziegner et al. reported
14 patients with diverse primary immunodeﬁcienciesHeof whom one child had SCID and developed a pro-
gressive neurodegenerative process. These patients
were on chronic IVIG therapy. The course of the
neurological illness was chronic, no infectious agent
was isolated; and neuro-imaging revealed cerebral
atrophy with ventricular dilation.20 In our patient,
an infectious etiology seems most plausible. The neu-
rological illness occurred in the background of diar-
rhoea and pneumonia. Recurrent convulsions,
hemiplegia and altered sensorium occurring acutely
indicated an infection, auto-immune process or a vas-
cular etiology. However, involvement of the limbic
structures such as the insular cortex, cingulate gyrus,
and temporal areas on MR imaging combined with
bi-PLEDs would suggest an infective etiology such
as herpes simplex virus or CMV infection. Moreover,
conﬁrmatory evidence in the form of virus isolation or
was not forthcoming. A brain biopsy was not agreed
to. Neurological manifestations have not been de-
scribed so far in RAG1 mutations. Whether the
new genetic defect identiﬁed in this patient may have
a predilection for CNS involvement by mechanisms
yet to be discovered, or whether he had unidentiﬁed
infective encephalitis, cannot be ascertained. However,
due to the consanguineity background, there is also a
possibility that two independent disorders may co-
segregate. The likelihood of a second disorder like
mitochondrial or genetic neurological disorder is pos-
sible but we could not test for them.
The pioneers in the ﬁeld of haploidentical stem cell
transplants for SCID, Reisner et al., successfully
achieved stable immune reconstitution in SCID pa-
tients with T-cell depleted HLA-haploidentical
parental grafts.21 Since then several other groups have
reported success rates varying from 54% to 77% for
haplo-transplants.22,23 Factors found to be predictive
of a poor outcome are an older age at transplant
(>5 months), B-SCID, functional NK cells, infec-
tions, and graft versus host disease.22,23 Most authors
have shown higher success rates with the use of a
cytoreductive conditioning regimen and T cell deple-
tion of the graft. However, T cell depletion is best
avoided in the presence of active infection. Children
with viral CNS infections have a dismal course even
if transplant is done at an appropriate time.15 Taking
into consideration the unfavourable circumstances in
our child, we opted for a T-cell replete graft, and fol-
lowed a mini-haplo transplant protocol which has
been described in 217 patients with advanced haema-
tological malignancies.24 We omitted the conditioning
regimen in this case as pre-existing organ damage was
extensive and ﬂudarabine is known to be neurotoxic.
Cyclophosphamide was given post-transplant on daymatol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
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+3 and day +4. There is compelling evidence derived
from both murine and human models which suggests
that cyclophosphamide administered at a critical time
point post-transplant selectively ablates activated allo-
reactive T-lymphocytes, and prevents graft versus host
disease.25 The rationale for choosing the mother as
the donor was derived from studies which have shown
that transplacental passage of maternal cells during
pregnancy establishes long term maternal micro-chi-
merism in the child, which facilitates engraftment by
inducing immune tolerance to the graft.26
Factors contributing to non-engraftment in our
patient were the absence of maternal cells in the child,Hematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comdelay in transplant, NK+ phenotype, and a lack of
conditioning regimen.
The distinctive features in this case were the pres-
ence of neutropenia and a progressive encephalopathy.
We suspect that these features could be linked to the
novel genetic defect but more data is required to
establish this conclusively.CONFLICT OF INTEREST
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